SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last)

(First)

(Middle)

609 SW 8TH STREET

SUITE 365

(Street)

BENTONVILLE

72712

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/31/2021

3. Issuer Name and Ticker or Trading Symbol
BiomX Inc. [ PHGE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,637,846⁽¹⁾⁽²⁾	I	By SymBiosis, LLC

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrants to purchase Common Stock	01/28/2022	01/28/2027	Common Stock	1,875,000⁽¹⁾⁽²⁾	$5	I	By SymBiosis, LLC

Explanation of Responses:

1. The shares are directly held by SymBiosis, LLC. Previously, the beneficial owner of these shares was Thomas Layton Walton, by virtue of his sole voting power and dispositive power through SymBiosis, LLC. Although SymBiosis, LLC continues to hold these shares directly and Thomas Layton Walton continues to hold his pecuniary interest in these shares, the reporting person now exercises sole voting power and dispositive power through SymBiosis, LLC through a transition of that power to the reporting person (and not through a sale or other transfer of these shares).

2. These shares beneficially owned by the reporting person include (i) 1,137,846 shares of common stock already owned by SymBiosis, LLC prior to July 28, 2021, (ii) 2,500,000 shares of common stock owned by SymBiosis, LLC that were purchased in the registered direct offering by BiomX Inc. that closed on July 28, 2021 and (iii) warrants (to purchase 1,875,000 shares of common stock) owned by SymBiosis, LLC that were purchased in the registered direct offering by BiomX Inc. that closed on July 28, 2021.

	/s/ Chidozie Ugsumba	02/13/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.